Infringement action filed 3 Oct 2025 in the United States District Court for the District of Delaware and closed 16 Jun 2026, with US10130646B1 asserted. Recorded basis of termination: consent judgment.
A terminally sterilized aqueous calcium gluconate solution comprising 1 to 15 wt. % calcium gluconate and from 1 to 19 wt. parts of calcium saccharate per 100 wt. parts of calcium gluconate packaged in a flexible plastic container with the remainder water.
Source: case record + Patsnap company data. Attorney names appear as recorded in the docket.Compare both portfolios
Outcome
Basis of termination
From the record · verbatim
"WHEREAS Plaintiffs HQ Specialty Pharma Corp. and WG Critical Care, LLC (collectively, “Plaintiffs”) brought this suit against Defendant Sagent Pharmaceuticals a/k/a Sagent Pharmaceuticals (Inc.) (“Defendant”) asserting infringement of U.S. Patent No. 10,130,646 (the “’646 patent”); NOW, THEREFORE, IT IS HEREBY STIPULATED by Plaintiffs and Defendant, subject to approval of this Court, that: 1. All claims and counterclaims between Plaintiffs and Defendant are dismissed without prejudice. 2. Each party shall bear its own costs, attorneys’ fees and expenses incurred in connection with the claims and counterclaims dismissed by this Order. 3. Defendant is enjoined from making, having made, importing, using, offering for sale, or selling terminally sterilized Calcium Gluconate in sodium chloride injection bag products which are the subject of Sagent’s Abbreviated New Drug Application No. 219619 (the “Sagent Products”) in the United States during the term of the ’646 patent, unless licensed by Plaintiffs.4. The Court retains jurisdiction over the parties to this action for purposes of enforcing this Stipulation and Consent Judgment. 5. This Stipulation and Consent Judgment shall not act as an adjudication on the merits. 6. The Clerk of the Court is directed to enter this Stipulation and Consent Judgment forthwith. 7. Nothing herein prohibits or is intended to prohibit Defendant from maintaining, modifying or filing any “Paragraph IV Certification” pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or pursuant to 21 C.F.R. § 314.94(a)(12) with respect to the Sagent Products or any application therefor. 8. Nothing herein prohibits or is intended to prohibit any party from engaging in any activity permitted under 35 U.S.C. § 271(e)(1)."
Case 1:25-cv-01227 · D. Del. · closed 16 June 2026
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
1:25-cv-01227 is a patent infringement action brought by HQ Specialty Pharma, Corp. against Sagent Pharmaceuticals, filed on 3 Oct 2025 in the United States District Court for the District of Delaware. The case closed on 16 June 2026.
Which patent was asserted in 1:25-cv-01227?
US10130646B1 (“Calcium gluconate solutions in flexible containers”), assigned to HQ SPECIALTY PHARMA CORPORATION, currently active. The record also lists Calcium Gluconate in sodium chloride (1 g/50 mL and 2 g/100 mL) solutions and calcium gluconate in sodium chloride (1 g/50 mL and 2 g/100 mL) solutions.
How was case 1:25-cv-01227 terminated?
The recorded basis of termination is consent judgment. The termination text reads: "WHEREAS Plaintiffs HQ Specialty Pharma Corp. and WG Critical Care, LLC (collectively, “Plaintiffs”) brought this suit against Defendant Sagent Pharmaceuticals a/k/a Sagent Pharmaceuticals (Inc.) (“Defendant”) asserting infringement of U.S. Patent No. 10,130,646 (the “’646 patent”); NOW, THEREFORE, IT IS HEREBY STIPULATED by Plaintiffs and Defendant, subject to approval of this Court, that: 1. All claims and counterclaims between Plaintiffs and Defendant are dismissed without prejudice. 2. Each party shall bear its own costs, attorneys’ fees and expenses incurred in connection with the claims
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 1:25-cv-01227 take?
256 calendar days, from filing on 3 Oct 2025 to closure on 16 June 2026.
Who were the attorneys and the judge in 1:25-cv-01227?
Chief Judge Maryellen Noreika presided. Andrew C. Stewart, Cameron Paul Clark, Megan Elizabeth Dellinger, Sharon L. Davis and Steven Lieberman are recorded as counsel for plaintiff HQ Specialty Pharma. Aaron M. Johnson, Cortlan S. Hitch and Kenneth Laurence Dorsney appear for defendant Sagent Pharmaceuticals.
Answers reproduce fields from the case record for 1:25-cv-01227 and do not constitute legal advice.Ask your own question
Disclaimer. This page reproduces publicly available court docket data for case 1:25-cv-01227 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.
Patsnap Eureka
Eureka AI Agent
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.